Compare Novartis AG (NVS) vs J M Smucker Co (SJM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs J M Smucker Co — how do they compare? Novartis AG trades at $143.75 (market cap $268.57B), while J M Smucker Co trades at $119.43 (market cap $12.76B). The key difference: Novartis AG is far larger — about 21× J M Smucker Co's market cap, and J M Smucker Co pays the higher dividend (3.75%). Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and J M Smucker Co for 74 Days on average.
| NVS | SJM | |
|---|---|---|
Market Cap | $268.57B | $12.76B |
Volume | 1,532,573 | 1,300,545 |
Sector | Health | Consumer Staples |
52-Week High | $168.62 | $132.34 |
52-Week Low | $121.80 | $89.53 |
Typical Hold Time | 82 Days | 74 Days |
Enterprise Value | $309.89B | $19.61B |
Dividend Yield | 3.31% | 3.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.75, up 0.33% on the day, near the consensus price target of $146.00. Recent earnings show mixed quarterly beats and a miss in Q1 2026, with revenue growth to $56.67B in 2025 and a net income margin of 24.67%. Technical indicators signal a bearish trend, while analyst sentiment is mixed with 24% buy ratings. The company recently announced a $7.8B licensing deal with China's Abogen for mRNA therapy, but faces scrutiny over clinical setbacks and M&A strategy.
The outlook for NVS hinges on execution of its pipeline and deal integration amid investor caution. Opportunities include expansion into autoimmune treatments and solid profitability, but risks involve trial failures, regulatory probes, and debt levels rising to 30.26% of assets. Wall Street remains neutral with a slight upside to the price target.
SJM trades at $119.83, up 3.36% today, with a bullish technical signal and recent earnings beats. The company reported strong Q2 2026 EPS of $3.24 versus $2.22 expected, though 2025 net income was negative $1.23B. Valuation ratios include a P/E of 55.8 and P/S of 1.39, with analyst consensus price target at $138.23.
Outlook is positive with raised 2027 guidance, but risks include volatile profitability and high debt. The stock offers a dividend yield from the upcoming $1.12 payment, supported by institutional buying. Earnings momentum and brand strength provide upside, yet margin pressures and competitive threats remain key watchpoints.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
